
Brand Name | Status | Last Update |
|---|---|---|
| simulect | Biologic Licensing Application | 2025-08-11 |
Expiration | Code | ||
|---|---|---|---|
basiliximab, Simulect, Novartis Pharmaceuticals Corporation | |||
| 2105-05-12 | Orphan excl. | ||
Code | Description |
|---|---|
| J0480 | Injection, basiliximab, 20 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | 2 | 7 | 10 | 9 | — | 25 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 5 | 4 | — | 9 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | 1 | 2 | — | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | 1 | 2 | — | 3 |
| Graft vs host disease | D006086 | — | D89.81 | — | — | 1 | 1 | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | 1 | — | 2 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | — | — | 1 | — | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | 1 | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychology rejection | D012059 | — | — | 2 | 2 | 2 | — | — | 4 |
| Organ transplantation | D016377 | — | — | — | — | 2 | — | — | 2 |
| Hepatitis c | D006526 | — | B19.2 | — | — | 2 | — | — | 2 |
| Graft rejection | D006084 | — | — | — | — | 1 | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | 1 | — | — | 1 |
| Alpha 1-antitrypsin deficiency | D019896 | — | E88.01 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
| Epstein-barr virus infections | D020031 | EFO_0000769 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Immunosuppression therapy | D007165 | — | — | — | — | — | — | 1 | 1 |
| Polyomavirus infections | D027601 | EFO_0007451 | — | — | — | — | — | 1 | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Basiliximab |
| INN | basiliximab |
| Description | Basiliximab (chimeric mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | >3IU3:A,C,H|Heavy chain of Fab fragment of Basiliximab
QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYME
LSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP
>3IU3:B,D,L|Light chain of Fab fragment of Basiliximab
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAE
DAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE |
| PDB | 3IU3 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201439 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00074 |
| UNII ID | 9927MT646M (ChemIDplus, GSRS) |

